Impact of Semaglutide on Body Composition in Adults with Overweight Or Obesity: Exploratory Analysis of the STEP 1 Study John Wilding
Impact of Semaglutide on Body Composition in Adults with Overweight or Obesity: Exploratory Analysis of the STEP 1 Study John Wilding. University of Liverpool John PH Wilding, DM, FRCP1, Rachel L. Batterham, MD, PhD2, Salvatore Calanna, PhD3, Luc F. Van Gaal, MD,PhD4, Barbara M. McGowan, MD, PhD5, Julio Rosenstock, MD6, Marie TD Tran, MD, PhD3, Sean Wharton, MD, PharmD7, Koutaro Yokote, MD, PhD8, Niels Zeuthen, MSc3, Robert F. Kushner, MD9. 1Obesity and Endocrinology Research, Department of Cardiovascular and Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, 2University College London Centre for Obesity Research, Division of Medicine, University College London and National Institute of Health Research, UCLH Biomedical Research Centre and Centre for Weight Management and Metabolic Surgery, UCLH, London, United Kingdom, 3Novo Nordisk A/S, Søborg, Denmark, 4Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, University of Antwerp, Edegem, Belgium, 5Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, 6Dallas Diabetes Research Center at Medical City, Dallas, TX, 7York University, McMaster University and Wharton Weight Management Clinic, Toronto, ON, Canada, 8Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University and Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan, 9Division of Endocrinology, Feinberg School of Medicine, Northwestern University, Chicago, IL. Background: Central obesity is associated with increased risk of cardiometabolic disease. Weight loss reduces lean muscle mass, potentially impacting resting energy expenditure and/or physical functioning. This analysis of the STEP 1 trial evaluated the impact of subcutaneous (s.c.) semaglutide, a glucagon-like peptide-1 analogue, on body composition in adults with overweight/obesity using dual energy X-ray absorptiometry (DEXA).
[Show full text]